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Elevated c-Src protein expression has been demonstrated in breast cancer and in vitro 
evidence suggests a role in endocrine resistance. To investigate whether c-Src is 
involved in endocrine resistance, we examined the expression of both total and 
activated c-Src in human breast cancer specimens from a cohort of oestrogen receptor 
(ER) positive tamoxifen treated breast cancer patients. 
Tissue microarray technology was employed to analyse 262 tumour specimens taken 
prior to tamoxifen treatment. Immunohistochemistry using total c-Src and activated c-
Src antibodies was performed. Kaplan-Meier survival curves were constructed and 
log rank test were performed.  
High level of nuclear activated Src was significantly associated with improved overall 
survival (p=0.047) and lower recurrence rates on tamoxifen (p=0.02). Improved 
patient outcome was only seen with activated Src in the nucleus. Nuclear activated 
Src expression was significantly associated with node negative disease and a lower 
NPI (p<0.05). On subgroup analysis, only ER positive/ Progesterone receptor (PgR) 
positive tumours were associated with improved survival (p=0.004). 
This demonstrates that c-Src activity is increased in breast cancer and that activated 
Src within the nucleus of ER positive tumours predicts an improved outcome.  In 
ER/PgR positive disease activated Src Kinase does not appear to be involved in 
endocrine resistance. Further work is required in ER negative breast cancer as this 
may represent a cohort in which it is associated with poor outcome. 
Key words. ER positive breast cancer, c-Src activation, nuclear, tamoxifen  
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Introduction  
Adjuvant hormone therapy results in substantial improvements in disease free and 
overall survival for woman with early hormone receptor positive breast cancer (Early 
Breast Cancer Trialists’ Collaborative Group, 1998 and 2005). Despite these benefits, 
a substantial proportion of patients will develop de novo or acquired resistance to 
hormone therapy and this presents a significant clinical problem. 
The precise molecular mechanisms involved in breast cancer cell resistance to 
endocrine therapy is poorly understood but there is strong evidence suggesting it 
involves crosstalk between the ER, growth factor receptors and other downstream 
cellular signalling pathways (Osborne & Schiff, 2004) resulting in ligand-independent 
activation of the ER and tumour cell growth. Indeed, we previously demonstrated that 
HER 1-3 expression is significantly associated with early relapse in an ER+, 
tamoxifen treated cohort (Tovey et al, 2005). Evidence is now emerging that 
endocrine resistance not only results in oestrogen independent growth but is also 
associated with altered cell-cell and cell-matrix adhesive interactions, promoting a 
more invasive phenotype (Hiscox et al, 2006).   
c-Src non receptor tyrosine kinase is over expressed and activated in a large number 
of human malignancies and the relationship between activation and cancer 
progression appears significant (Irby & Yeatman, 2000). The precise mechanism of 
its action has not been fully elucidated, but c-Src is known to interact with a diverse 
array of molecules, including growth factor receptors and cell-cell adhesion receptors, 
integrins and steroid receptors including the ER (Ishizawar & Parsons, 2004 and 
Shupnik, 2004) promoting tumour cell proliferation, survival, differentiation, 
migration and invasion (Yeatman, 2004 and Frame, 2004). Recent in vitro studies 
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have demonstrated the over expression and over activity of Src during the acquisition 
of tamoxifen resistance in ER positive cell lines (Planas-Silva et al, 2006 and Hiscox 
et al, 2005). Src inhibition was seen to significantly reduce the invasive behaviour of 
these cells. In addition, inhibition of c-Src has been shown to reduce the incidence of 
breast cancer metastases and increases survival in mice. Progress in knowledge of c-
Src in tumour genesis  and has resulted in Src Kinase inhibition being investigated as 
a therapeutic target for anti invasive therapies in breast cancer (Finn et al, 2007 and 
Rucci et al, 2006). 
This study, using a large cohort of ER positive (+) tamoxifen treated patients, was 
undertaken to examine if c-Src expression is involved in de novo resistance to 
tamoxifen treatment. We examine the role of c-Src expression in human ER positive 
breast cancers, to determine if in vivo c-Src expression, activation or cellular location 
is associated with response to tamoxifen therapy and patient survival. 
Material & Methods 
Patients and tissues 
 
The local ethics committee granted ethical approval for this study to utilise a database 
that details the outcome of ER positive patients diagnosed with primary operable 
breast cancer between 1980 and 1999 treated with adjuvant tamoxifen.  Within this 
cohort all patients received adjuvant tamoxifen (mean time 4.8 years), 26 % of 
patients received adjuvant chemotherapy and 18% received adjuvant  radiotherapy. 
Formalin fixed paraffin embedded tissue, taken at time of surgical resection, was used 
for tissue microarray (TMA) construction, as described previously (Tovey et al, 
2005).  
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Immunohistochemistry.  
 
Immunohistochemistry was performed on 10 normal breast sections and 10 prostate 
cancer samples, in addition to the 262 ER positive breast cancer specimens. Full 
activation of c-Src requires phosphorylation at tyrosine (Tyr) 419 in addition to the 
absence of phosphorylation at tyrosine 519. A phosphospecific antibody (Cell 
Signalling, Technology) raised in rabbit to phosphorylated Y416, SrcpY416 which 
corresponds to human Tyr 419 was used, as described in the literature (Planas-Silva et 
al, 2006). In addition an antibody recognising Total Src (36D10, Cell Signalling 
Technology) was used.  Prior to performing immunohistochemistry, antibody 
specificity was confirmed by western blotting (figure 1). As expected, activated c-Src, 
SrcpY416, was detected as a single 60kDa band and decreased in response to the Src 
kinase inhibitor dasatinib. Titration of the optimal antibody dilution was undertaken in 
breast tumour specimens prior to the procedure.  
Tissue sections were dewaxed and rehydrated through graded alcohols and then 
subject to heat induced antigen retrieval by pressure steaming in preheated 10mM 
citrate buffer for 5 mins. Immunostaining was then performed; sections were first 
treated with hydrogen peroxide and then blocked using horse serum, followed by 
incubation in primary antibody (1: 50 dilution, SrcpY416 overnight) (1: 200 for 
Src36D10, 1 hour). DakoCytomation EnVision was applied for 30 mins and sections 
incubated with DAB (1:50 dilution). Finally, sections were counterstained, dehydrated 
and mounted. Positive and negative (isotype matched antibody) control slides were 
incorporated in each run. 
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Tissue staining intensity was scored blind by 2 independent observers using a 
weighted histoscore method (Kirkegaard et al, 2006) also known as the Hscore 
system (McCarty et al,1986). Histoscores were calculated from the sum of (1 x % 
cells staining weakly positive) + (2 x % cell staining moderately positive) + (3 x % 
cells staining strongly positive) with a maximum of 300.  Each cellular location was 
separately assessed with a weighted histoscore assigned to any membrane, cytoplasm 
and nucleus staining.  The histoscores for each core were then averaged. Where one 
core was missing the remaining core(s) scores were used.  To determine high and low 
expression the median value for all scores was used. The inter-class correlation 
coefficient (ICCC) for each protein was calculated to confirm consistency between 
observers. 
 
Western blot analysis.  
 
MCF-7 cells treated with varying concentrations of dasatinib were lysed in RIPA 
buffer (50 mM Tris pH7.6, 150 mM sodium chloride, 1% Triton X-100, 0.5% 
deoxycholate, 0.1% SDS, 10 mM sodium fluoride, 1 mM sodium ortho-vanadate and 
1:100 Calbiochem protease inhibitor cocktail set 1) and centrifuged at 12 000 rpm for 
10 min, the supernatant removed and protein concentration determined using 
BCA/CuSO4 assay. 40 µg of protein per well was resolved by 4-12% gradient Bis-
Tris gel electrophoresis (Invitrogen, UK); proteins were transferred to nitrocellulose 
membranes (Millipore, UK), which were blocked for 1 hour in 5% BSA and probed 
with primary antibodies: anti-phospho SrcY419 (1:10000) and anti-total Src (1:10000 
Cell Signaling Technologies, UK) at 40C overnight. Membranes were then incubated 
with secondary antibodies (anti-rabbit 1:5000 or anti-mouse 1:5000, Cell Signalling 
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Technologies) and visualized with ECL kit (Amersham, UK). Where necessary, the 
membranes were stripped by incubating with Re-Blot Plus stripping buffer 
(Chemicon, UK) before re-probing with other antibodies including anti-αTubulin 
(1:8000 Santa Cruz, USA) to confirm equal protein loading. 
Statistical analysis. 
The statistical software package SPSS version 11.5 was used for all analysis. 
Interclass correlation coefficient was employed to confirm consistency between 
observers. Protein expression data were not normally distributed and are shown as 
median and inter quartile ranges.  Pearson Chi Square test was employed to assess 
association between staining intensity and known clinical parameters and survival 
analyses were conducted using Kaplan-Meier method, curves were compared with the 
log-rank test.  Hazard ratios (HR) were calculated using Cox Regression analysis.   
 
Results 
Clinical & pathological characteristics.  
Clinical and pathological characteristics for all patients (n=262), including age, grade, 
nodal status, histology, size and Nottingham Prognostic Index are detailed in Table 1. 
The mean duration of tamoxifen therapy was 4.82 years. 55 patients (21%) had breast 
cancer specific deaths, 77 patients (29.4%) had breast cancer relapse, 60 of these 
patients while receiving tamoxifen therapy. 
 
Localisation of Total Src and activated c-Src in normal breast 
Ten normal breast sections were stained for total Src and activated c-Src. Low 
expression oftotal Src was observed in the cytoplasm of 60% and nucleus of 40%, 
however no activated c-Src expression was observed at any location 
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Localisation of activated c-Src expression in ER positive breast cancer tissue 
A total of 262 ER positive tumour samples were analysed for activated c-Src 
expression. 57.3% (150/262) of tumours expressed activated Src in the cytoplasm; 
median histoscore 20 (interquartile range 0-61.5).  58.4% (153/262) of tumours 
expressed activated c-Src in the nucleus; median histoscore 10 (interquartile range 0-
45). High levels (greater than the median value) of activated c-Src expression in the 
cytoplasm or nucleus was therefore detectable in over 50% (n=153) of all ER positive 
breast tumours analysed. 2.7% (7/260, 2 samples missing) of tumours expressed 
activated Src in the membrane, median histoscore 0. Due to the low rate of membrane 
expression observed it was not deemed appropriate to apply these results to further 
statistical tests. In order to confirm that the antibody was able to detect membrane 
staining 10 prostate tumours were also stained for activated c-Src. Activated c-Src 
was much more commonly located to the cell membrane of prostate cells compared to 
the ER positive breast carcinomas.  Figure 2 illustrates the staining patterns observed 
in the ER positive breast cancer specimens compared to prostate cancer specimens. 
 
Activated c-Src and patient outcome 
High expression level (above the median value) of activated c-Src within the nucleus 
of tumour cells was significantly associated with improved overall survival (p=0.047) 
and decreased recurrence in tamoxifen treated patients (p=0.02), figure 3a-b. On cox 
regression analysis this was not demonstrated to be independent for survival or 
recurrence. The location of activated c-Src around the nucleus was also significant, 
tumours with uniform staining had improved outcome in comparison to patients with 
only perinuclear staining (figure 3c, p=0.0153). Activated c-Src within the cell 
cytoplasm was not significantly associated with patient outcome. 
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Activated c-Src and prognostic indices 
Activated c-Src within the nucleus was associated with node negativity and low NPI 
(Pearson-Chi Square, p=0.03 and p=0.046 respectively).  Activated c-Src within the 
cytoplasm of cells was not associated with nodal status, NPI, tumour grade or size. No 
significant correlation was found with Ki67 (proliferative index).  In contrast when 
the cohort was subdivided by Progesterone receptor (PgR) status (histoscore >10), 
activate c-Src nuclear expression remained highly significant in the ER and PgR + 
subgroup (n=165, p=0.004).  However in the ER+/ PgR negative subgroup 
significance was lost (n=93, p=0.56).  PgR status was not available for 4 tumours 
from our cohort of 262 patients.  The cohort was not stratified for HER2 status as only 
4 tumours were found to be positive using the Herceptest. 
 
Total Src expression in ER positive breast cancer 
Of the 262 patients only 231 tumour samples were scored for total Src expression. 
95.8% (220/231) of tumours expressed total Src in the cytoplasm, median histoscore 
97 (interquartile range 40-150).  70.6% (153/230) of tumours expressed total Src in 
the cell membrane, median histoscore 26 (interquartile range 0-95). No total Src was 
seen within the cell nucleus. Total Src expression (at any location) was not 
significantly associated with any clinical parameters or patient outcome. 
 
Discussion 
 
Although cell line studies strongly support the role of c-Src in endocrine resistant 
breast cancer progression, translational studies investigating human breast tumour 
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expression, activation and correlation with clinical parameters are surprisingly 
limited. Using a large cohort of ER positive breast cancer patients treated with 
adjuvant tamoxifen we have shown that high levels of activated c-Src are present in 
over 50% of tumour specimens and we also demonstrate that nuclear c-src activation 
is significantly associated with improved overall and disease free survival. Subgroup 
analysis demonstrates that this benefit is only seen in ER+/PgR+ patients and not 
within ER+/PgR negative group.   
As c-Src is a non receptor tyrosine kinase that is localized to the intracellular 
membranes and cytoplasm of the cell (Biscardi et al, 2000) it was surprisingly that in 
the current study we rarely observed activated c-Src in the cell membrane.  However 
antibody specificity was confirmed by western blotting. A single 60kDa band 
suggesting that phosphorylated Src kinase was detected. In addition, phosphorylation 
of c-Src (but not total c-Src) was observed to fall following treatment with increasing 
concentrations of the Src kinase inhibitor dasatinib confirming that the antibody 
detected phosphorylated Src only (figure 1).  Although these experiments confirmed 
that the antibody used in the study was specific for phosphorylated Src kinase, it did 
not answer the question about the location of phosphorylated Src observed in this 
cohort. We therefore stained prostate tumours to assess the localisation of activated 
Src in a different tumour type. In prostate cancer the majority of staining observed for 
phosphorylated Src was located to the membrane and nuclear expression was rarely 
observed. These results suggest that the lack of membrane staining and high level of 
nuclear staining observed in the current study was associated with our ER positive 
breast cancer cohort, and was not a characteristic of the antibody used. However the 
Y416  sequence is highly conserved amongst the src kinases so this does not exclude 
detection of other src family kinases along with c-Src using this antibody. Our 
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detection of nuclear c-src expression and activation is in line with recent literature as 
c-Src has been reported both within the nucleus and nucleolus (David-Pfeuty et al, 
1993 & 1995) of other solid tumours. Previous immunohistochemical work 
demonstrated that in non malignant breast cells c-Src is distributed within the 
cytoplasm, whereas in malignant breast cells the majority of c-Src appears 
concentrated around the nucleus (Verbeek et al,1996). 
In this present study we found that high levels of activated c-Src was present in over 
50% tumour specimens analysed and nuclear activated c-Src was significantly 
associated with improved overall survival and decreased recurrence.   Ito et al, 2001 
also found that elevated activated cSrc was inversely correlated with biological 
aggressiveness in 73 breast cancer specimens and suggested that c-Src may have an 
important role in malignant transformation of breast cells rather than malignant 
progression. Madan et al, 2006 subsequently demonstrated that c-Src activation did 
not correlate with the development of invasive tumour properties but correlated with 
malignant transformation. In ductal carcinoma in situ, activated c-Src was found to 
correlate with high tumour grade, high proliferation and HER 2 positivity, suggesting 
that high cSrc activity may identify a subset of DCIS at risk of disease progression to 
invasive carcinoma (Wilson et al, 2006). 
The body of evidence does, however, still support a role for c-Src in malignant 
progression.  Compared with adjacent normal tissues, elevated Src expression and/or 
activity has been reported in a wide range of tumour types, including breast cancer 
(Verbeek et al, 1996) and in many of these tissues, an increase in Src activity 
correlates with disease stage or malignant potential (Aligayer et al 2002 and Weiner 
et al, 2003). Tumour cell lines possessing elevated Src activity are often highly 
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metastatic, displaying an increased capacity for migration and invasion in vitro (Mao 
et al 1997, Jackson et al 2000, Slack et al 2001).  
Recent in vitro breast cell line work, demonstrate over expression and over activity of 
Src during the acquisition of tamoxifen resistance in ER+ cell line (Planas-Silva et al, 
2006 and Hiscox et al, 2005). Src inhibition was seen to significantly reduce the 
invasive behaviour of cells. Hiscox et al  found elevated Src kinase activity in 
endocrine resistance models was independent of Src gene or protein level. Tamoxifen 
resistance may be either de novo (present before tamoxifen treatment) or “acquired”. 
In this present study all analysis was performed on tumour samples taken prior to 
tamoxifen treatment and whilst we do not find that active c-Src correlates with de 
novo endocrine resistance it is interesting that within our cohort the survival benefit 
was only in ER+/PgR+ patients and not in the ER+/PgR negative group. PgR 
expression is a marker of a functional ER and a number of laboratory studies have 
demonstrated the importance of molecular characteristics such as PgR and HER2 in 
predicting tumour response to endocrine therapy. We have previously reported that 
ER+/PgR negative tumours are more likely to relapse on tamoxifen (Tovey et al, 
2005) and a number of other laboratory studies report a reduction in PgR expression 
in ER+ cells is consistent with acquired tamoxifen resistance (Scott et al, 2007). It is 
therefore possible that in tumours with a functioning ER (ER+/PgR+) “active” cSrc is 
in the nucleus and not able to perform its role in promoting tumour progression. 
Tumours acquiring tamoxifen resistance over time have an adaptive change in growth 
factor signalling (such as a reduction in PgR expression, increased EGFR expression), 
therefore Src kinase being downstream of such signalling networks may not become 
fully active until later during the development of tamoxifen resistance. High levels of 
activated cSrc expression in the cell cytoplasm have been reported in recurrent breast 
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carcinoma samples (Planas-Silva et al, 2006) although expression was not compared 
with the primary tumour sample. Comparison of primary breast tumour cSrc 
expression with expression in recurrent or metastatic tumours following endocrine 
resistance would be a preferable model. Within our laboratory we have examined this 
in prostate cancer specimens. In hormone sensitive prostate cancer active cSrc was 
associated with improved survival but after development of hormone therapy 
resistance, active cSrc was associated with reduced time to death (unpublished data). 
It is also likely that our patient cohort represents a good prognostic group and that the 
aggressive phenotype associated with Src kinase is limited to poor prognostic cancers. 
Indeed Finn et al, 2007  recently reported a highly significant relationship between 
breast cancer cell line sub type based on gene expression of cytokeratins and 
sensitivity to src kinase inhibition, suggesting that the “triple negative” breast cancers 
were most likely to benefit from Src inhibition. ER negative tumours correlate with 
poor tumour differentiation, high proliferation rate and other unfavourable 
characteristics, and are in general considered a more aggressive breast carcinoma. An 
inverse correlation between Src and ER levels has been reported, ER negative primary 
breast cancer and cell lines showed increased Src levels and/ or activity compared to 
ER + cancers (Chu  et al, 2007).  
 
In conclusion, we found elevated levels of activated cSrc within the cell nucleus of 
ER+ breast cancer was associated with improved patient outcome in a large cohort of 
Tamoxifen treated ER positive patients. Although we are unable to substantiate the in 
vitro studies suggesting a role for c-Src in tamoxifen resistance we feel that further 
clarification defining the role of cSrc in the different subtypes of breast cancer, 
particularly in ER negative breast cancer and recurrent tumours, is warranted as this 
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likely represents the group in which targeted Src Kinase inhibition may be beneficial 
to patient outcome. 
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Table 1. Patient clinical and pathological variables 
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 Number Valid% 
Grade 
1 60 23.3% 
2 124 48.2% 
3 73 28.4% 
unknown 5  
Nodal Status 
0 128 53.3% 
1-3 72 30% 
4+ 40 16.7% 
unknown 22  
Histological type 218 83.2% 
ductal 20 7.6% 
lobular 24 9.2% 
Other (incl. unknown) 
Size (mm) 89 36.3% 
T1(<20) 149 59.1% 
T2 (20-50) 14 5.6% 
T3 (>50) 10  
unknown 
NPI 66 35.5% 
<3.5 94 50.5% 
3.5-5.5 26 14% 
>5.5 76  
unknown 
Age (years) 42 16% 
</=50 220 84% 
>50 
Chemotherapy 68/262 26% 
yes 194/262 74% 
no   
Progesterone Receptor (PgR) status 
PgR + 165  
PgR- 93  
PgR unknown 4  
 
Note: Grade= Bloom and Richardson grade. Nodal status= number of positive nodes, Histological 
type: ductal, invasive ductal carcinoma; lobular, invasive lobular carcinoma; other includes 
mucinous, mucoid etc. 
Abbreviation: NPI, Nottingham Prognostic Index (grade+ nodal status+ 0.02x size in mm) 
 
      
 
Figure Legends 
Figure 1 shows western blot experiment. Phosphospecific antibody recognising 
activated c-Src ( SrcpY416) is demonstrated as a single 60kDa band (lane 1- 
control, C). In addition phosphorylation of c-Src was observed to fall following 
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treatment with increasing concentrations of the Src kinase inhibitor dasatinib 
(lanes2-6) and total Src were not affected by this. Tubulin was used as a control. 
 
Figure 2 demonstrates the different localisation of activated c-Src, SrcpY416 in 
prostate and breast tumour samples. In breast tumours activated c-Src was most 
commonly present in the cell cytoplasm and cell nucleus (2a & 2b).  In the 
prostate cancer (2c & 2d) the majority of staining observed for phosphorylated c-
Src was located to the membrane and nuclear expression was rarely observed.  
 
Figure 3. Kaplan Meier survival curves, 3a shows overall survival difference 
between ER+ patients with high (above the median value) and low expression of 
activated nuclear c-Src. p=0.047; 3b one minus survival curve demonstrating 
disease recurrence in ER+ patients with high and low expression of activated  
nuclear c-Src. p=0.02; 3c demonstrates overall survival differences between 
activated c-Src depending on pattern of nuclear staining. Uniform nuclear staining 
was significantly associated with improved survival compared to no nuclear 
staining or only perinuclear. p=0.0153. 
  
 
 
 
Figure 1 
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Figure 2 
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